{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:09Z","timestamp":1792800009849,"version":"4.5.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"27","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The benefits of heart rate (HR)-lowering drug treatment in hypertension remain controversial. The effects of HR lowering on cardiovascular (CV) outcomes, mortality, and adverse events in patients with hypertension and\/or CV disease were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, the Embase, and the Cochrane Library were searched for randomized trials comparing HR-lowering drugs with placebo or less intensive treatment. Risk ratios and 95% confidence intervals for eight outcomes were calculated (random-effects model). Subgroup analyses for a standard HR reduction were used to compare risk estimates in different HR groups or age strata (PROSPERO CRD42024540924).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The database included 74 HR-lowering treatment trials (n = 157 764 patients). The average HR reduction over 2.7 years was 8.2\u2005b.p.m. (baseline\/attained HR: 76.2\/65.6\u2005b.p.m.). HR-lowering reduced coronary heart disease by 16%, heart failure by 9%, CV mortality by 14%, and all-cause mortality by 13% but increased adverse event-driven discontinuations by 25%. Significant mortality reductions were noted in post-acute myocardial infarction and heart failure. No significant outcome changes were observed with HR reduction in hypertension without CV disease, while the entire hypertensive population experienced increased stroke and mortality. Threshold analysis revealed that the effect on outcomes was not different across cutoffs (from \u226580\u2005b.p.m. to almost 70\u2005b.p.m.), except for heart failure. Treatment outcome effects were not different across progressively lower targets (from \u226570\u2005b.p.m. to &amp;lt;65\u2005b.p.m.), except for permanent discontinuations, which showed an incremental trend.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The HR reduction benefits are context-dependent. Optimising outcomes while considering potential risks, targeting 65\u201370\u2005b.p.m. for all HR thresholds above 70\u2005b.p.m. seems reasonable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf291","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:21:50Z","timestamp":1745580110000},"page":"2657-2669","source":"Crossref","is-referenced-by-count":26,"title":["Heart rate-lowering drugs and outcomes in hypertension and\/or cardiovascular disease: a meta-analysis"],"prefix":"10.1093","volume":"46","author":[{"given":"Elias","family":"Sanidas","sequence":"first","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg (Saar) ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra","family":"Oikonomopoulou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Dinopoulou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Michalopoulou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":false,"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Cardiology Clinic, Hippokration Hospital, University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Milano-Bicocca , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-6029","authenticated-orcid":false,"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Laiko General Hospital of Athens , 17, Agiou Thoma str., Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"2025071406514405300_ehaf291-B1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","article-title":"Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease","volume":"128","author":"B\u00f6hm","year":"2015","journal-title":"Am J Med"},{"key":"2025071406514405300_ehaf291-B2","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/0002-8703(93)90128-V","article-title":"Influence of heart rate on mortality among persons with hypertension: the Framingham Study","volume":"125","author":"Gillman","year":"1993","journal-title":"Am Heart J"},{"key":"2025071406514405300_ehaf291-B3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1755-5922.2012.00321.x","article-title":"Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand?","volume":"31","author":"Menown","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"2025071406514405300_ehaf291-B6","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B7","doi-asserted-by":"publisher","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"2025071406514405300_ehaf291-B8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"2025071406514405300_ehaf291-B9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","article-title":"Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal","volume":"116","author":"Zanchetti","year":"2015","journal-title":"Circ Res"},{"key":"2025071406514405300_ehaf291-B10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.921","article-title":"The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology","volume":"19","author":"van Bilsen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B11","doi-asserted-by":"publisher","first-page":"h4451","DOI":"10.1136\/bmj.h4451","article-title":"Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data","volume":"351","author":"Ziff","year":"2015","journal-title":"BMJ"},{"key":"2025071406514405300_ehaf291-B12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","article-title":"Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure","volume":"33","author":"Castagno","year":"2012","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.amjmed.2008.09.043","article-title":"Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis","volume":"122","author":"Bangalore","year":"2009","journal-title":"Am J Med"},{"key":"2025071406514405300_ehaf291-B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"B\u00f6hm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2025071406514405300_ehaf291-B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ahj.2013.04.016","article-title":"Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease","volume":"166","author":"B\u00f6hm","year":"2013","journal-title":"Am Heart J"},{"key":"2025071406514405300_ehaf291-B16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000000841","article-title":"Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes","volume":"34","author":"Hirakawa","year":"2016","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025071406514405300_ehaf291-B18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025071406514405300_ehaf291-B19","volume-title":"GRADE handbook. Grading of Recommendations Assessment, Development and Evaluation","author":"Schumemann","year":"2013"},{"key":"2025071406514405300_ehaf291-B20","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs\u2014overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B22","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0002-9149(85)90396-0","article-title":"A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy","volume":"55","author":"Anderson","year":"1985","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia\/New Zealand Heart Failure Research Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0002-9149(90)90831-K","article-title":"Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol","volume":"66","author":"Boissel","year":"1990","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1161\/01.CIR.90.2.762","article-title":"Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The atenolol silent ischemia study (ASIST)","volume":"90","author":"Pepine","year":"1994","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/oxfordjournals.eurheartj.a061482","article-title":"The effect of pindolol on the two years mortality after complicated myocardial infarction","volume":"4","author":"Australian and Swedish Pindolol Study Group","year":"1983","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/hrt.44.1.96","article-title":"Multicentre postinfarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia","volume":"44","author":"Baber","year":"1980","journal-title":"Br Heart J"},{"key":"2025071406514405300_ehaf291-B30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study","volume":"36","author":"Barill\u00e0","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2025071406514405300_ehaf291-B31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.CIR.96.1.183","article-title":"Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial","volume":"96","author":"Basu","year":"1997","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B32","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low-dose metoprolol CR\/XL and fluvastatin slow progression of carotid intima media thickness: main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS)","volume":"103","author":"Hedblad","year":"2001","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1388-9842(02)00032-6","article-title":"The incomplete bucindolol evaluation in acute myocardial infarction trial (BEAT)","volume":"4","author":"Torp-Pedersen","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.0954-6820.1986.tb02790.x","article-title":"Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10\u2013year controlled trial with bendroflumethiazide","volume":"220","author":"Berglund","year":"1986","journal-title":"Acta Med Scand"},{"key":"2025071406514405300_ehaf291-B36","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Beta-Blocker Evaluation of Survival Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B37","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B38","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B39","doi-asserted-by":"publisher","first-page":"e0199347","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"2025071406514405300_ehaf291-B40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejheart.2003.12.019","article-title":"Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)","volume":"6","author":"Komajda","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B42","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9149(00)00796-7","article-title":"Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD group","volume":"85","author":"Witchitz","year":"2000","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0140-6736(03)13801-9","article-title":"Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial","volume":"362","author":"Cleland","year":"2003","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B45","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B46","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS Investigators and Committees","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B47","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514405300_ehaf291-B48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","article-title":"Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol heart failure study group","volume":"3","author":"Cohn","year":"1997","journal-title":"J Card Fail"},{"key":"2025071406514405300_ehaf291-B49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B50","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1067\/mhj.2002.121807","article-title":"Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure","volume":"144","author":"de Milliano","year":"2002","journal-title":"Am Heart J"},{"key":"2025071406514405300_ehaf291-B51","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.eurheartj.a061636","article-title":"European infarction study (E.I.S.). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality","volume":"5","year":"1984","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B53","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","article-title":"Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study","volume":"7","author":"Edes","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1161\/01.CIR.72.3.536","article-title":"Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial","volume":"72","author":"Engelmeier","year":"1985","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/bmj.284.6310.155","article-title":"One year\u2019s treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial","volume":"284","author":"Hansteen","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2025071406514405300_ehaf291-B57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B58","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514405300_ehaf291-B59","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). the IPPPSH collaborative group","volume":"3","year":"1985","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B61","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B62","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of ivabradine in Japanese patients with chronic heart failure- J-SHIFT study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2025071406514405300_ehaf291-B63","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for one year after myocardial infarction","volume":"319","author":"Julian","year":"1982","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B64","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B65","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B66","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/bmj.3.5986.735","article-title":"Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study","volume":"3","year":"1975","journal-title":"Br Med J"},{"key":"2025071406514405300_ehaf291-B67","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1253\/circj.CJ-10-1078","article-title":"Secondary preventive effects of a calcium antagonist for ischemic heart attack: randomized parallel comparison with b-blockers","volume":"75","author":"Nakagomi","year":"2011","journal-title":"Circ J"},{"key":"2025071406514405300_ehaf291-B68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"Norwegian Multicentre Study Group","year":"1981","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B69","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0735-1097(85)80360-0","article-title":"Long term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity","volume":"5","author":"Olsson","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514405300_ehaf291-B70","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B71","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective randomized evaluation of carvedilol on symptoms and exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","article-title":"PredischaRge initiation of ivabradine in the ManagEment of heart failure: results of the PRIME-HF trial","volume":"223","author":"Mentz","year":"2020","journal-title":"Am Heart J"},{"key":"2025071406514405300_ehaf291-B73","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","author":"The RESOLVD Investigators","year":"2000","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B74","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/hrt.34.3.252","article-title":"Effects of a beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset","volume":"34","author":"Reynolds","year":"1972","journal-title":"Br Heart J"},{"key":"2025071406514405300_ehaf291-B75","first-page":"115","article-title":"Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (rimodellamento infarto miocardico acuto) study. The RIMA researchers","volume":"29","author":"Coletta","year":"1999","journal-title":"G Ital Cardiol"},{"key":"2025071406514405300_ehaf291-B76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B77","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B78","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B79","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/0002-9149(93)90291-J","article-title":"Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD investigators. Spanish study on sudden death","volume":"72","author":"Navarro-L\u00f3pez","year":"1993","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B80","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJM198211183072101","article-title":"A long term prevention study with oxprenolol in coronary heart disease","volume":"307","author":"Taylor","year":"1982","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/oxfordjournals.eurheartj.a014668","article-title":"Total ischaemic burden European trial (TIBET). effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group","volume":"17","author":"Dargie","year":"1996","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B82","doi-asserted-by":"publisher","first-page":"182S","DOI":"10.1093\/ajh\/5.6.182S","article-title":"Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial","volume":"5","author":"Yurenev","year":"1992","journal-title":"Am J Hypertens"},{"key":"2025071406514405300_ehaf291-B83","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1001\/jama.1982.03330160052024","article-title":"Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy","volume":"248","author":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","year":"1982","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B84","doi-asserted-by":"publisher","first-page":"630","DOI":"10.26502\/fccm.92920159","article-title":"Value of ivabradine in patients with anterior ST-elevation myocardial infarction: the VIVA-STEMI study","volume":"4","author":"Rezq","year":"2020","journal-title":"Cardiol Cardiovasc Med"},{"key":"2025071406514405300_ehaf291-B85","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"key":"2025071406514405300_ehaf291-B86","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/bmj.280.6218.885","article-title":"Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction","volume":"280","author":"Wilcox","year":"1980","journal-title":"Br Med J"},{"key":"2025071406514405300_ehaf291-B87","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction","volume":"319","author":"Multicenter Diltiazem Postinfarction Trial Research Group","year":"1988","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B88","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0002-9149(90)90351-Z","article-title":"Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II--DAVIT II)","volume":"66","year":"1990","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B89","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/oxfordjournals.eurheartj.a061701","article-title":"Verapamil in acute myocardial infarction. The Danish study group on verapamil in myocardial infarction","volume":"5","year":"1984","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B90","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1161\/01.CIR.99.20.2645","article-title":"Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure","volume":"99","author":"Kukin","year":"1999","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B91","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/clc.4960150808","article-title":"The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The visacor study group","volume":"15","author":"Boberg","year":"1992","journal-title":"Clin Cardiol"},{"key":"2025071406514405300_ehaf291-B92","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0002-9149(97)89365-4","article-title":"A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS)","volume":"77","author":"Rengo","year":"1996","journal-title":"Am J Cardiol"},{"key":"2025071406514405300_ehaf291-B93","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cardfail.2011.05.001","article-title":"Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients","volume":"17","author":"Marazzi","year":"2011","journal-title":"J Card Fail"},{"key":"2025071406514405300_ehaf291-B94","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA"},{"key":"2025071406514405300_ehaf291-B95","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1161\/01.CIR.101.7.758","article-title":"Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality assessment in congestive heart failure trial","volume":"101","author":"Levine","year":"2000","journal-title":"Circulation"},{"key":"2025071406514405300_ehaf291-B96","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/oxfordjournals.bmb.a072892","article-title":"Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease","volume":"50","author":"Collins","year":"1994","journal-title":"Br Med Bull"},{"key":"2025071406514405300_ehaf291-B97","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"2025071406514405300_ehaf291-B98","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000435947","article-title":"Heart rate, life expectancy and the cardiovascular system: therapeutic considerations","volume":"132","author":"Boudoulas","year":"2015","journal-title":"Cardiology"},{"key":"2025071406514405300_ehaf291-B99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03007995.2024.2305248","article-title":"Sympathetic overactivity, hypertension and cardiovascular disease: state of the art","volume":"40","author":"Grassi","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025071406514405300_ehaf291-B100","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/01.HYP.34.4.598","article-title":"Heart rate-dependent stiffening of large arteries in intact and sympathectomized rats","volume":"34","author":"Mircoli","year":"1999","journal-title":"Hypertension"},{"key":"2025071406514405300_ehaf291-B101","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1161\/01.HYP.0000085199.33254.15","article-title":"Effects of heart rate changes on arterial distensibility in humans","volume":"42","author":"Giannattasio","year":"2003","journal-title":"Hypertension"},{"key":"2025071406514405300_ehaf291-B102","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jacc.2009.02.088","article-title":"Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (conduit artery function evaluation) study: CAFE-heart rate","volume":"54","author":"Williams","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514405300_ehaf291-B103","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ana.26480","article-title":"Low heart rate is associated with cerebral pulsatility after TIA or minor stroke","volume":"92","author":"Webb","year":"2022","journal-title":"Ann Neurol"},{"key":"2025071406514405300_ehaf291-B104","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/joim.12373","article-title":"Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET\/TRANSCEND studies","volume":"278","author":"B\u00f6hm","year":"2015","journal-title":"J Intern Med"},{"key":"2025071406514405300_ehaf291-B105","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (candesartan in heart failure: assessment of reduction in mortality and morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514405300_ehaf291-B106","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B107","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/eurheartj\/ehy808","article-title":"Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET\/TRANSCEND trials","volume":"41","author":"B\u00f6hm","year":"2020","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"2025071406514405300_ehaf291-B109","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ejhf.2677","article-title":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-preserved trial","volume":"24","author":"B\u00f6hm","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025071406514405300_ehaf291-B110","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/HJH.0000000000001777","article-title":"Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14\u2014effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis","volume":"36","author":"Thomopoulos","year":"2018","journal-title":"J Hypertens"},{"key":"2025071406514405300_ehaf291-B111","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/eurheartj\/ehm489","article-title":"Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials","volume":"28","author":"Cucherat","year":"2007","journal-title":"Eur Heart J"},{"key":"2025071406514405300_ehaf291-B112","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"2025071406514405300_ehaf291-B113","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/27\/2657\/63011292\/ehaf291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/27\/2657\/63011292\/ehaf291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:51:50Z","timestamp":1752490310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/27\/2657\/8120051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":113,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2025,4,25]]},"published-print":{"date-parts":[[2025,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf291","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,14]]},"published":{"date-parts":[[2025,4,25]]}}}